ArticleJournal of oncology2022

Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma.

Guoqiang Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.